Product Information

AVALIDE 300-12.5 MG TABLET is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $9.7125 per EA under NDC 00024585630. Its NADAC has been published 247 times since Nov 28, 2013.

The High Outlier badge above means this manufacturer's average price in the irbesartan and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

AVALIDE 300-12.5 MG TABLET

irbesartan and hydrochlorothiazide

$9.7125per EA

High Outlier

Strength

12.5; 300 mg/1; mg/1

Manufacturer

Sanofi-Aventis U.S. LLC

NDC

00024585630

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

8/21/2024

Active Ingredients

HYDROCHLOROTHIAZIDE; IRBESARTAN

Approval Type

New Drug (NDA)

FDA Application

NDA020758

On Market Since

1/1/2013

Pharmacological Classes

Angiotensin 2 Receptor Antagonists

Angiotensin 2 Receptor Blocker

Increased Diuresis

Thiazide Diuretic

Thiazides

Price Statistics

The NADAC for AVALIDE 300-12.5 MG TABLET has been published 247 times since Nov 28, 2013, and over the history we have for it it has risen 114.1%. The table below summarizes its recorded NADAC range and movement.

Current price	$9.7125 per EA
All-time high	$9.7125 (Aug 13, 2025)
All-time low	$4.4750 (Jan 22, 2014)
52-week high	$9.7125
52-week low	$9.7125
Median price	$6.6029
Average price	$7.0718
Largest weekly change	+33.2% (Apr 17, 2024)
Weeks tracked	247
Tracking since	Nov 28, 2013

Price History

0.0%

+33.7%

All

+114.1%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the irbesartan and hydrochlorothiazide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Frequently asked questions

What is the NADAC price of AVALIDE 300-12.5 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for AVALIDE 300-12.5 MG TABLET, manufactured by Sanofi-Aventis U.S. LLC, is $9.7125 per EA (NDC 00024585630), effective Aug 13, 2025.

How has the price of AVALIDE 300-12.5 MG TABLET changed over time?

Over the history we have for it, the NADAC for AVALIDE 300-12.5 MG TABLET has risen 114.1%. It has been tracked across 247 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for AVALIDE 300-12.5 MG TABLET?

Since Nov 28, 2013, the NADAC for AVALIDE 300-12.5 MG TABLET has ranged from a low of $4.4750 (Jan 22, 2014) to a high of $9.7125 (Aug 13, 2025), with a median of $6.6029 per EA.

Are there cheaper alternatives to AVALIDE 300-12.5 MG TABLET?

No other NADAC-published product currently shares the active ingredient, strength, and dosage form of AVALIDE 300-12.5 MG TABLET, so no direct lower-cost alternative is listed.